Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Denali Therapeutics in a research report issued to ...
Jefferies (NYSE:JEF) analyst Michael Yee maintained a Buy rating on Denali Therapeutics (NASDAQ:DNLI) on Sunday, setting a price target of $95, which is approximately 48.67%... Evercore ISI ...
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Carole Ho, the Chief Medical (TASE:PMCN) Officer of Denali Therapeutics Inc. (NASDAQ:DNLI), has recently sold shares of the company's common stock, according to a filing... On January 6 and 7, Ryan J.
The Nasdaq Composite soared 252 points on Wednesday.AI-related tech stocks gave the markets a boost, Companies such as Nvidia (), Oracle (), and Arm Holdings jumped on President Trump's new AI ...
Inclusion is central to all we do at Nasdaq. That’s why we’re working hard on improving our digital accessibility, so our products and platforms are easy to use and intuitive to navigate for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback